Analysts have been eager to weigh in on the Healthcare sector with new ratings on Exact Sciences (EXAS – Research Report), Alnylam Pharma (ALNY – Research Report) and Catalent (CTLT – Research Report).
Exact Sciences (EXAS)
In a report released today, Bruce Jackson from Benchmark Co. reiterated a Buy rating on Exact Sciences, with a price target of $91.00. The company’s shares closed last Friday at $60.97, close to its 52-week low of $58.37.
According to TipRanks.com, Jackson ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $89.67.
See the top stocks recommended by analysts >>
Alnylam Pharma (ALNY)
RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma today and set a price target of $235.00. The company’s shares closed last Friday at $147.00, close to its 52-week low of $143.52.
According to TipRanks.com, Issi has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $220.85, representing a 49.2% upside. In a report issued on February 8, Canaccord Genuity also maintained a Buy rating on the stock with a $284.00 price target.
Catalent (CTLT)
RBC Capital analyst Sean Dodge maintained a Hold rating on Catalent today and set a price target of $63.50. The company’s shares closed last Friday at $58.14.
According to TipRanks.com, Dodge is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Catalent with a $60.75 average price target, representing a 5.1% upside. In a report issued on February 5, Nephron also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EXAS:
- LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy?
- Is EXAS a Buy, Before Earnings?
- BIIB, ZTS, EXAS: Which “Strong Buy” Healthcare Stock is Best?
- Exact Sciences (NASDAQ:EXAS) Announces Strong Preliminary Q4 Results and CFO Transition
- Exact Sciences says Jeff Elliott stepping down as executive VP, CFO
